In addition to classical Aβ and tau targets, a variety of targets such as cholinergic, glutaminergic, dopaminergic, GABAergic, adrenergic, and serotonergic signaling have been extensively studied as possible pathways for the treatment of AD (Kandimalla and Reddy, 2017). The gene discussed is MAPT; the disease is Alzheimer disease.